Complement C1s activation in degenerating articular cartilage of rheumatoid arthritis patients: immunohistochemical studies with an active form specific antibody

Koichi Nakagawa, Hisako Sakiyama, Toyomitsu Tsuchida, Kiichiro Yamaguchi, Toru Toyoguchi, Riako Masuda, Hideshige Moriya

Abstract

Objective—The first complement component C1s was reported to have novel functions to degrade matrix components, besides its activities in the classic complement pathway. This study explores participation of C1s in articular cartilage degradation in rheumatoid arthritis (RA).

Methods—Normal articular cartilage (n=6) and cartilage obtained from joints with RA (n=15) and osteoarthritis (OA, n=10) were immunostained using anti-C1s monoclonal antibodies PG11, which recognises both active and inactive C1s, and M241, which is specifically reactive to activated C1s. The effects of inflammatory cytokines on C1s production by human articular chondrocytes were also examined by sandwich ELISA.

Results—In normal articular cartilage, C1s was negative in staining with both PG11 and M241. In contrast, degenerating cartilage of RA was stained with PG11 (14 of 15 cases), and in most of the cases (13 of 15 cases) C1s was activated as revealed by M241 staining. In OA, C1s staining was restricted in severely degrading part of cartilage (5 of 10 cases), and even in that part C1s was not activated. In addition, C1s production by chondrocytes in vitro was increased by an inflammatory cytokine, tumour necrosis factor α.

Conclusion—These results suggest that C1s activated in degenerative cartilage matrix of RA but not in that of OA. C1s is thought to participate in the pathogenesis of RA through its collagenolytic activity in addition to the role in the classic cascade.

Autoimmunity is thought to be one of the dominant factors in the destruction of joint cartilage in rheumatoid arthritis (RA). Previous studies have demonstrated the presence of autoantibodies reacting with cartilage components in the serum samples of RA patients. These cartilage specific antigens include components of cartilage matrix such as type II collagen, as well as of cellular elements. Although such antibodies have regulatory roles in T cell activation, the consequences of a direct antibody-cartilage interaction has also been pointed out. There is little doubt that complement activation occurs adjacent to the cartilage surfaces of RA patients as evidenced by the abundant co-deposits of immunoglobulin and activated complement components on the surface. Furthermore, it has been reported that chondrocytes themselves synthesise the components. Cytotoxic effects of the complement system is thought to play an important pathological part in the processes leading to irreversible cartilage damage in RA.

The first complement component C1s is activated by C1r, which is autoactivated upon binding of C1q to an immune complex. Activated C1s cleaves C2 and C4 to form C3 convertase and starts the classic pathway. Recently, C1s was shown to have novel functions to degrade types I, II, and IV collagen, gelatin, and decorin and to activate the zymogen of matrix metalloproteinase-9. Moreover, we have found that C1s is expressed in hamster epiphyseal chondrocytes and intensely immunostained in the hypertrophic chondrocytes, but not in normal articular chondrocytes. We also found that C1s was activated on the edge of degrading cartilage fragments at the ossification centre, where the cartilage matrix is replaced by bone marrow. These findings suggest possible participation of C1s in cartilage remodelling.

Similar to physiological chondrolysis during development, pathological destruction of articular cartilage in RA and osteoarthritis (OA) is known to be caused, at least partially, by chondrocyte derived proteolytic enzymes such as matrix metalloproteinases. In inflammatory arthritis, C1s may also participate in cartilage degradation through its proteolytic activities and cytotoxicities by activating the classic complement cascade. To ascertain C1s participation in the pathogenesis of RA, we examined localisation and activation of C1s in articular cartilage with RA and OA by immunostaining using anti-C1s monoclonal antibodies.

Methods

PATIENTS AND TISSUE ACQUISITION

Articular cartilage from 31 patients were studied after obtaining informed consent. Table 1 shows the clinical details of the patients. Macroscopically normal, full thickness articular cartilage was obtained from four patients with femoral neck fracture undergoing joint replacement surgery, and two patients with chondrosarcoma undergoing amputation before radiation therapy or chemotherapy. Articular
cartilage of 10 patients with OA and 15 patients with diagnosis of RA, according to the American College of Rheumatology criteria, were obtained at time of knee or hip joint replacement surgery. All RA patients were treated with disease modifying anti-rheumatic drugs (DMARDs) and low dose prednisone (less than 10 mg daily). Cartilage tissues were acquired from not only degenerating sites but also macroscopically normal sites of OA and RA joints. All tissues were fixed with 4% paraformaldehyde in phosphate buffered saline immediately after operation.

TABLE 1 Detailed information of each patient examined in the study

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex/age (y)</th>
<th>Diagnosis</th>
<th>Joint</th>
<th>Patient</th>
<th>Sex/age (y)</th>
<th>Diagnosis</th>
<th>Duration (y)</th>
<th>Joint</th>
<th>Activity</th>
<th>Stage*</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-1</td>
<td>F/70</td>
<td>FNF</td>
<td>Hip</td>
<td>R-1</td>
<td>F/56</td>
<td>RA</td>
<td>15</td>
<td>Knee</td>
<td>Active</td>
<td>III</td>
</tr>
<tr>
<td>2 F/64</td>
<td>FNF</td>
<td>Hip</td>
<td></td>
<td>2 F/37</td>
<td>RA</td>
<td>14</td>
<td>Knee Active III</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 F/74</td>
<td>FNF</td>
<td>Hip</td>
<td></td>
<td>3 F/51</td>
<td>RA</td>
<td>8</td>
<td>Knee Active III</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 F/85</td>
<td>FNF</td>
<td>Hip</td>
<td></td>
<td>4 F/59</td>
<td>RA</td>
<td>10</td>
<td>Knee Active III</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 M/18</td>
<td>CS</td>
<td>Knee</td>
<td></td>
<td>5 F/67</td>
<td>RA</td>
<td>20</td>
<td>Knee Active III</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 F/18</td>
<td>FS</td>
<td>Ankle</td>
<td></td>
<td>6 F/58</td>
<td>RA</td>
<td>11</td>
<td>Knee Active III</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O-1</td>
<td>F/57</td>
<td>OA</td>
<td>Hip</td>
<td>7 F/72</td>
<td>RA</td>
<td>23</td>
<td>Knee Active III</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 F/73</td>
<td>OA</td>
<td>Hip</td>
<td></td>
<td>8 F/36</td>
<td>RA</td>
<td>4</td>
<td>Knee Active III</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 F/63</td>
<td>OA</td>
<td>Knee</td>
<td></td>
<td>9 F/53</td>
<td>RA</td>
<td>21</td>
<td>Knee Active III</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 F/77</td>
<td>OA</td>
<td>Knee</td>
<td></td>
<td>10 F/76</td>
<td>RA</td>
<td>21</td>
<td>Knee Active III</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 F/72</td>
<td>OA</td>
<td>Knee</td>
<td></td>
<td>11 F/50</td>
<td>RA</td>
<td>12</td>
<td>Knee Inactive III</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 F/67</td>
<td>OA</td>
<td>Knee</td>
<td></td>
<td>12 F/61</td>
<td>RA</td>
<td>20</td>
<td>Knee Inactive III</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 F/75</td>
<td>OA</td>
<td>Knee</td>
<td></td>
<td>13 F/41</td>
<td>RA</td>
<td>9</td>
<td>Knee Inactive III</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 F/64</td>
<td>OA</td>
<td>Knee</td>
<td></td>
<td>14 F/52</td>
<td>RA</td>
<td>9</td>
<td>Knee Inactive III</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 F/75</td>
<td>OA</td>
<td>Knee</td>
<td></td>
<td>15 M/65</td>
<td>RA</td>
<td>14</td>
<td>Knee Inactive III</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 F/67</td>
<td>OA</td>
<td>Knee</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Figure 1 Immunostaining of C1s in normal and OA articular cartilage. Articular cartilage obtained from knee joints of a normal person (A, B: 18 year old man) and a patient with OA (C, D, E, F: 75 year old woman) was fixed with 4% paraformaldehyde as described in the text. Frozen sections were immunostained with PG11 (A, C), M241 (D), and NG7 (B, E, for control staining). Parallel serial sections were stained with toluidine blue (F). In normal articular cartilage, neither chondrocytes nor matrix were stained with PG11 (A). In the degrading part of OA cartilage, superficial cartilage matrix (arrowheads) and chondrocytes (large arrows) but not chondrocytes in the deep zone (small arrow) was reactive to PG11 (C). However, active form C1s was not detected in the cartilage by immunostaining with M241 (D). Bar: 100 µm.

Figure 1 Immunostaining of C1s in normal and OA articular cartilage. Articular cartilage obtained from knee joints of a normal person (A, B: 18 year old man) and a patient with OA (C, D, E, F: 75 year old woman) was fixed with 4% paraformaldehyde as described in the text. Frozen sections were immunostained with PG11 (A, C), M241 (D), and NG7 (B, E, for control staining). Parallel serial sections were stained with toluidine blue (F). In normal articular cartilage, neither chondrocytes nor matrix were stained with PG11 (A). In the degrading part of OA cartilage, superficial cartilage matrix (arrowheads) and chondrocytes (large arrows) but not chondrocytes in the deep zone (small arrow) was reactive to PG11 (C). However, active form C1s was not detected in the cartilage by immunostaining with M241 (D). Bar: 100 µm.

Figure 1 Immunostaining of C1s in normal and OA articular cartilage. Articular cartilage obtained from knee joints of a normal person (A, B: 18 year old man) and a patient with OA (C, D, E, F: 75 year old woman) was fixed with 4% paraformaldehyde as described in the text. Frozen sections were immunostained with PG11 (A, C), M241 (D), and NG7 (B, E, for control staining). Parallel serial sections were stained with toluidine blue (F). In normal articular cartilage, neither chondrocytes nor matrix were stained with PG11 (A). In the degrading part of OA cartilage, superficial cartilage matrix (arrowheads) and chondrocytes (large arrows) but not chondrocytes in the deep zone (small arrow) was reactive to PG11 (C). However, active form C1s was not detected in the cartilage by immunostaining with M241 (D). Bar: 100 µm.

SERUM C reactive peptide measurement
Serum C reactive peptide (CRP) of each patient was measured by using N Latex CRP Kit (Hoechst Japan, Tokyo, Japan).

Antibodies
Characterisation of anti-human C1s monoclonal antibodies M81, M365, and M241 have been reported. M81 and M365 recognise around the C4 binding site of human C1s, and react with both active and inactive C1s. M241, a neutralising antibody, binds specifically to the active centre of activated C1s. These three antibodies are kind gifts from Dr M Matsumoto. Anti-hamster C1s monoclonal antibodies PG11 and NG7 have also been characterised previously. PG11 recognises the same epitope as M81, and cross reacts with human C1s. NG7 shows low cross reactivity with human C1s, and was used for control staining.

Immunohistochemical studies
Articular cartilage fixed with paraformaldehyde was decalcified with 20% EDTA in 0.15 M NaCl solution, and frozen in OCT compound (Miles Scientific, Naperville, Ill, USA). Serial sections were prepared for haematoxylin and eosin, toluidine blue (pH 7.0), and immunohistochemical staining. For immunostaining, the sections were treated with PG11 (50 µg/ml) or M241 (50 µg/ml) at 4°C overnight, followed by an incubation with biotinylated goat antimiouse IgG F(ab)2 (Boehringer Mannheim Biochemical, Mannheim, Germany) for three hours. The samples were then incubated with horseradish peroxidase (HRP) conjugated streptavidin (Boehringer Mannheim Biochemical, Mannheim, Germany), and counter stained with haematoxylin.
CELL CULTURE AND QUANTIFICATION OF C1s IN CONDITIONED MEDIA

Normal articular cartilage was obtained from amputated lower extremities of young patients with informed consent. For isolation of chondrocytes, the finely diced tissues were digested with 0.2% collagenase (type IV, Sigma Chemical, St Louis, MO, USA) in minimal essential medium plus 10% fetal calf serum (FCS) for three hours. Isolated chondrocytes were cultured in a 1:1 mixture of Dulbecco’s modified Eagle’s medium and F-12 (DMEM+F-12), supplemented with 20% FCS. To examine effects of inflammatory cytokines on C1s production, the first passage human articular chondrocytes were incubated at a density of $3 \times 10^6$ cells/well in 96 well plates and grown in 0.2 ml of the medium described above. After reaching confluency (four days after inoculation), the culture medium was switched to 0.1 ml of serum free DMEM+F-12 supplemented with human transferrin (10 µg/ml), bovine insulin (10 µg/ml), and hydrocortisone (10$^{-8}$ M). Various concentrations of recombinant human interleukin 1 (IL1, Boehringer Mannheim Biochemica, Mannheim, Germany) or human tumour necrosis factor α (TNFα, Boehringer Mannheim Biochemica, Mannheim, Germany) were added and incubated for 48 hours. Conditioned media were collected and C1s in the media was quantified by sandwich ELISA as described previously.$^{39}$ Briefly, wells of 96 well flexible assay plates (Becton Dickinson Lobware, Oxnard, CA, USA) were coated with M365 (50 µg/ml), and reacted with samples for one hour at room temperature. After washing, the wells were incubated with biotinylated M81 (50 µg/ml), followed by alkaline phosphatase labelled avidin (10 µg/ml, E-Y Laboratories, Inc, San Mateo, CA, USA). The enzyme activity was assayed for 30 minutes at 37°C in 10% diethanolamine buffer (pH 9.8), 3.8 mM p-nitrophenyl phosphate (Sigma Chemical, St Louis, MO, USA) and 1 mM MgCl$_2$. Absorbance was measured at 405 nm with Immunoreader NJ-2000 (Nippon Inter Med, Ltd, Tokyo, Japan). C1s in the conditioned media was quantified using a standard curve drawn as previously described.$^{39}$

IMMUNOBLOTTING

Serum free conditioned medium of human articular chondrocytes was concentrated 50 times by ammonium sulphate precipitation, and the amount of total protein was examined by Lowry’s method. Samples (20 µg protein / lane) were analysed on SDS-PAGE (10% gel) under non-reducing condition. Immunoblotting was carried out using M81 (50 µg/ml).

STATISTICAL ANALYSIS

Statistical analysis was performed using Student’s $t$ test with Welch’s correction. Differences between groups were considered significant when the $p$ value was less than 0.05.

Results

IMMUNOHISTOCHEMICAL DETECTION OF ACTIVATED C1s IN HUMAN ARTICULAR CARTILAGE WITH RA

In normal articular cartilage, neither chondrocytes nor cartilage matrix was stained with an anti-C1s monoclonal antibody PG11 that recognises both active and inactive C1s (fig 1A). Naturally, normal cartilage was non-reactive to both M241, recognising only active C1s (data not shown), and NG7, an antihamster C1s monoclonal antibody that is poorly cross reactive to human C1s (fig 1B). In cartilage with OA, degrading superficial cartilage matrix (fig 1C arrowheads) and chondrocytes (fig 1C large arrows) were stained with PG11. In superficial areas with cartilage fibrillation, a

### Table 2 Summary of immunohistochemical examinations of C1s in human articular cartilage

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Chondrocytes (no of positive/no of examined)</th>
<th>Degenerating matrix (no of positive/no of examined)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PG11</td>
<td>0/6</td>
<td>0/6</td>
</tr>
<tr>
<td>M241</td>
<td>0/6</td>
<td>0/6</td>
</tr>
<tr>
<td>OA</td>
<td>5/10</td>
<td>0/10</td>
</tr>
<tr>
<td>RA active</td>
<td>10/10</td>
<td>10/10</td>
</tr>
<tr>
<td>RA inactive</td>
<td>4/5</td>
<td>4/5</td>
</tr>
</tbody>
</table>

Active RA: patients whose serum CRP was higher than 1.0 mg/dl. *Positive cells were localised to only degenerating superficial zone.

Figure 2 Differential reactivities of PG11 and M241 in RA articular cartilage. Articular cartilage of RA patients (A, C, E: 36 year old woman, B, D, F, G: 51 year old woman) was fixed and frozen sectioned as described in the text. The samples were immunostained with PG11 (A, B), M241 (C, D), and NG7 (E, F, for control staining) and stained with toluidine blue (G). Degenerative cartilage matrix was equally reactive to both PG11 (A, B arrowheads) and M241 (C, D arrowheads). Whereas, chondrocytes were stained with PG11 (A, B arrows) but not with M241 (C, D). Bar: 100 µm.
coincidental C1s detection and loss of proteoglycans was revealed by toluidine blue staining (fig 1F). However, C1s activation is thought to be minimal, if at all, as staining intensity by M241 (fig 1D) was equivalent to that of NG7 (fig 1E). The surface of degenerative articular cartilage of RA patients showed histopathological features such as fibrillation, clustering of chondrocytes, fibrocartilage formation (fig 2), and faint metachromasia by toluidine blue staining (fig 2G). In these regions, cartilage matrix was equally reactive to both PG11 (fig 2A, B arrow heads) and M241 (fig 2C, D arrow heads), indicating presence of C1s activation. In regions of pannus invasion, synovial fibroblasts (fig 3C) and tartrate resistant acid phosphatase (TRAP) positive multinucleated cells (fig 3E arrows) were infiltrating into the matrix. Invading synovial cells, degrading cartilage matrix and invading pannus were stained with PG11 (fig 2A), M241 (fig 2C), and NG7 (fig 1E), indicating presence of C1s activation.

Figure 3  Immunolocalisation and activation of C1s at the site of pannus formation. Articular cartilage with pannus was fixed, and serial frozen sections were prepared as described in the text. They were stained with haematoxolin and eosin (C), toluidine blue (F) and immunostained with PG11 (A), M241 (D), and NG7 (B). Tartrate resistant acid phosphatase (TRAP) staining was also performed (E). Invasion of synovial cells and TRAP positive multinucleate cells (E arrows) was observed in the cartilage matrix. Invading synovia and degrading cartilage matrix were intensely stained with PG11 (A). They also stained with M241 (D), indicating that C1s was activated there. Bar: 50 µm.

Figure 4  Effects of IL1 and TNFα on C1s production by human articular chondrocytes. (A) Serum free culture medium of human articular chondrocytes was analysed on SDS-PAGE (10% gel) under non-reducing condition and immunoblotted with M81. Lane 1; culture medium, lane 2; molecular marker, arrow; C1s. (B) Chondrocytes were seeded at a density of 3 × 10⁴ cells/well in 96 well plates and grown in DMEM+F12 supplemented with 20% PCS. After they reached confluency (four days), the culture medium was switched to serum free medium, DMEM+F-12 supplemented with human transferrin (10 µg/ml), bovine insulin (10 µg/ml), and hydrocortisone (10⁻⁸ M), containing various concentration of IL1α or TNFα, (control: no addition). After a 48 hour incubation period, C1s in the medium was quantified by sandwich ELISA and the amounts were normalised to cell number. Values are the average (SD) of four determinations (bars). * p<0.05; ** p<0.01 vs control.
Complement C1s activation in degenerating articular cartilage and RA

matrix (fig 3A arrowheads), and fibrous components were strongly stained with PG11 (fig 3A) and M241 (fig 3D). C1s in the cartilage matrix of RA is thought to be activated because of its reactivity to M241, which makes a striking difference from C1s in the OA cartilage matrix (fig 1D, table 2).

In RA cases, C1s positive chondrocytes were observed not only in degenerating superficial regions, but also in the mid and deep zones of cartilage (fig 2B arrows). In contrast, in OA cases, C1s positive chondrocytes were restricted mainly to the superficial and transitional zones where proteoglycans were depleted (compare fig 1C with fig 1F), but not seen in the deep zone of cartilage (fig 1C small arrows). In any case, no absolute evidence of M241 staining of chondrocytes were present (fig 1D, fig 2C, D), indicating the inactivity of C1s within cells. No degenerative articular cartilage with RA was immunostained with NG7 (fig 2E, F, fig 3B).

Table 2 summarises all C1s immunohistochemical examinations. C1s was detectable in none of the normal articular cartilage examined (0 of 6). In contrast, in half of the OA cases (5 of 10) and in almost all RA cases (14 of 15), cartilage was positive in C1s staining. In particular, intense C1s staining in both chondrocytes and cartilage matrix was observed in all cases diagnosed as active RA (10 of 10), whose serum CRP was over 1.0 mg/dl.

EFFECTS OF CYTOKINES ON C1s SYNTHESIS BY ARTICULAR CHONDROCYTES IN VITRO

The first passage chondrocytes grew into multilayer cell sheets after they reached confluency and produced proteoglycan rich matrix around them. Secretion of type II collagen into the medium was ascertained by immunoblotting and sandwich ELISA using anti-type II collagen monoclonal antibodies. The articular chondrocytes were shown to secrete C1s into the culture media by immunoblotting with M81 (fig 4A).

As cytokines are important mediators for inflammation, we examined if IL1α and TNFα had any effect on C1s production by articular chondrocytes by sandwich ELISA and immunostaining with anti-type II collagen antibodies. The articular chondrocytes were shown to synthesise C1s by both immunostaining with PG11 (fig 4A) and M241 (fig 3D). C1s in the cartilage matrix (fig 3A) and M241 (fig 3D). C1s in the cartilage matrix of RA is thought to be activated because of its reactivity to M241, which makes a striking difference from C1s in the OA cartilage matrix (fig 1D, table 2).

In RA cases, C1s positive chondrocytes were observed not only in degenerating superficial regions, but also in the mid and deep zones of cartilage (fig 2B arrows). In contrast, in OA cases, C1s positive chondrocytes were restricted mainly to the superficial and transitional zones where proteoglycans were depleted (compare fig 1C with fig 1F), but not seen in the deep zone of cartilage (fig 1C small arrows). In any case, no absolute evidence of M241 staining of chondrocytes were present (fig 1D, fig 2C, D), indicating the inactivity of C1s within cells. No degenerative articular cartilage with RA was immunostained with NG7 (fig 2E, F, fig 3B).

Table 2 summarises all C1s immunohistochemical examinations. C1s was detectable in none of the normal articular cartilage examined (0 of 6). In contrast, in half of the OA cases (5 of 10) and in almost all RA cases (14 of 15), cartilage was positive in C1s staining. In particular, intense C1s staining in both chondrocytes and cartilage matrix was observed in all cases diagnosed as active RA (10 of 10), whose serum CRP was over 1.0 mg/dl.

In this study, it was shown that C1s was not immunostained in normal articular cartilage either in chondrocytes or in cartilage matrix. In striking contrast, C1s was immunostained in articular cartilage with RA and OA in both chondrocytes and matrix, and activated in the superficial layer of RA matrix but not in that of OA. C1s in the matrix was thought to be derived from both synovial fluid and chondrocytes. Bradley et al have also reported that C1s was detected in human articular cartilage with OA by immunostaining and RT-PCR.39 Although C1s was not detected in chondrocytes of normal human articular cartilage, articular chondrocytes in vitro were shown to synthesise C1s. Gulati et al showed synthesis of C1s as well as that of C1r and C1 inhibitor by normal articular chondrocytes in vitro.40 These findings suggest that under physiological condition, C1s synthesis is suppressed in articular chondrocytes. Under pathological conditions such as RA and OA, chondrocytes initiate C1s synthesis by either removal of a putative suppressor(s) or generation of a stimulator(s) in the degenerating regions. Inflammatory cytokines, which stimulate chondrocytes in synthesising proteolytic enzymes including matrix metalloproteinases,32–34 were expected to be the stimulators. Other investigators have demonstrated that TNF increased more C1s synthesis than C1 inhibitor synthesis by fibroblasts.35 Our results show that TNF is an important mediator that increases C1s production by articular chondrocytes.

The striking differences in M241 staining between RA and OA are thought to reflect different amounts of active C1s in RA and OA. We think that C1s is activated in RA, but not in OA cartilage, although we cannot exclude a possibility that immunostaining with M241 was not sensitive enough to detect a small amount of active C1s in OA cartilage. These findings should have important aetiological significance for C1s in both cytotoxic effects on chondrocytes and matrix degradation in RA. It is not surprising that active C1s in RA cartilage matrix, because C1s activation is performed by C1r upon binding of C1q to antigen-antibody complexes, and a number of studies have shown the presence of antibodies against cartilage components in RA.14–16 In fact, co-deposits of immunoglobulin and complement components have been shown on the cartilage surfaces of RA patients.15–17 We also have observed coincident immunostaining of M241 and anti-C3b monoclonal antibody on cartilage with RA (unpublished data). C1s once activated, activates downstream activation of complement cascade and may cause an irreversible damage to chondrocytes.15–17 It is possible that chondrocyte derived C1s, secreted into the lacunae, participates in this reaction. In addition, C3b on the cartilage is thought to stimulate the phagocytosis by macrophages, resulting in further cartilage degradation. Another possible contribution of C1s activation in RA pathogenesis is its potency of direct matrix degradation, as it degrades matrix components such as type I, II, and IV collagens18,19 and decorin,20 and activates the zymogen of matrix metalloproteinase-9.21 Other types of proteolytic enzymes, such as matrix metalloproteinases, were shown to be produced by chondrocytes and play an important part in pathological destruction of articular cartilage in RA and OA.20–22 In RA, it is likely that de novo synthesised C1s promotes degradation of pericellular matrix.

In addition to type II collagen of other animals, we demonstrated that human C1s also degrades human type II collagen (data not shown). Type II collagen fragments cleaved by C1s at different sites from that of typical collagenase could be antigens for the autoimmune disease. There is considerable evidence showing the presence of antibodies against type II collagen fragments in serum samples of RA...
We are grateful to Dr M Matsumoto (Department of Immunology, Osaka Medical Centre for Cancer and Cardiovascular Disease, Osaka, Japan) for providing us with anti-human C1s monoclonal antibodies M81, M65, and M241. We thank Dr S Tazetaki, Dr A Hirose, Dr Y Harada, Dr H Shigeta, Dr M Sakamoto, Dr T Yonemoto, Dr R Kanayama, and Dr H Ota (The Department of Orthopaedic Surgery, Chiba University School of Medicine, Chiba, Japan) for cooperation in obtaining tissue samples. We also thank Dr K Tatsuni (The Division of Biology and Oncology, National Institute of Radiological Sciences, Chiba, Japan) for support, Ms K Kuriyama for technical assistance and Ms L R Bowman and Dr SH Sunimura for linguistic help. This work was supported in part by Special Coordination Funds for Promoting Science and Technology from the Science and Technology Agency of Japan.


4 Clague RB, Moore LJ. IgG and IgM antibody to native type II collagen in rheumatoid arthritis sera on chondrocytes. Behring Inst Mitt 1993;93:196--203.


Complement C1s activation in degenerating articular cartilage of rheumatoid arthritis patients: immunohistochemical studies with an active form specific antibody

Koichi Nakagawa, Hisako Sakiyama, Toyomitsu Tsuchida, Kiichiro Yamaguchi, Toru Toyoguchi, Rilako Masuda and Hideshige Moriya

Ann Rheum Dis 1999 58: 175-181
doi: 10.1136/ard.58.3.175

Updated information and services can be found at:
http://ard.bmj.com/content/58/3/175

These include:

References
This article cites 43 articles, 14 of which you can access for free at:
http://ard.bmj.com/content/58/3/175#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Immunology (including allergy) (5144)
- Connective tissue disease (4253)
- Degenerative joint disease (4641)
- Musculoskeletal syndromes (4951)
- Rheumatoid arthritis (3258)
- Osteoarthritis (931)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/